What it's for (Indications)
- Leucovorin is a reduced folate primarily indicated for several critical clinical scenarios.
- Its most well-known use is as a "rescue" agent following high-dose methotrexate therapy or in cases of inadvertent methotrexate overdose, to protect healthy cells from the cytotoxic effects of the antifolate drug.
- This is crucial in oncology to mitigate severe myelosuppression, mucositis, and nephrotoxicity.
- Additionally, leucovorin is extensively used in combination with 5-fluorouracil (5-FU) to enhance the cytotoxic effects of 5-FU in the treatment of various cancers, most notably advanced colorectal cancer.
- It also plays a role in the treatment of megaloblastic anemia due to folate deficiency when oral folate supplementation is not feasible, and in combination with pyrimethamine for the treatment of toxoplasmosis and *Pneumocystis jirovecii* pneumonia to ameliorate the hematologic toxicity of pyrimethamine.
- The specific application and dosage are highly dependent on the clinical context and concurrent therapies, requiring careful medical assessment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of leucovorin is highly variable and must be meticulously individualized based on the specific indication, the patient's clinical status, and the concurrent therapeutic regimen. For methotrexate rescue, dosing is complex, guided by serum methotrexate levels, duration of methotrexate exposure, and renal function. Leucovorin rescue is typically initiated within 24 hours of methotrexate administration and may continue for several days until methotrexate levels fall below a safe threshold. When used in combination with 5-fluorouracil for colorectal cancer, specific regimens are followed, which can involve daily or weekly administrations, often as an intravenous infusion. For megaloblastic anemia due to folate deficiency, daily oral or parenteral doses are prescribed until the deficiency is resolved. In the context of toxoplasmosis or *Pneumocystis jirovecii* pneumonia treatment with pyrimethamine, specific daily oral doses are used to counteract pyrimethamine's antifolate effects. It is imperative that leucovorin administration, especially for high-risk indications, occurs under the direct supervision of an experienced oncologist or healthcare professional knowledgeable in its use. |
Safety & Warnings
Common Side Effects
- Leucovorin itself is generally well-tolerated when administered alone and according to prescribed guidelines.
- However, when used in combination with other potent chemotherapeutic agents, particularly 5-fluorouracil (5-FU), it significantly enhances the toxicities of the concomitant drug.
- The most common adverse effects observed in combination regimens with 5-FU include increased gastrointestinal toxicities such as severe mucositis (stomatitis), diarrhea, nausea, and vomiting.
- Hematologic toxicities, including myelosuppression (leukopenia, thrombocytopenia, anemia), are also potentiated, necessitating frequent blood count monitoring.
- Rarely, allergic reactions such as urticaria, pruritus, rash, and anaphylactoid reactions can occur.
- High doses, particularly with intrathecal administration (which is generally discouraged and not a primary indication), have been associated with neurological effects including insomnia, agitation, depression, and very rarely, seizures.
- Any severe or unusual reactions should be reported immediately to a healthcare provider.
Serious Warnings
- Black Box Warning: Leucovorin itself does not carry a specific FDA Black Box Warning. However, its use, particularly in conjunction with other highly potent and toxic chemotherapeutic agents, necessitates extreme caution and strict adherence to specific protocols. **Serious Warnings Regarding Concomitant Therapies:** 1. **Potentiation of 5-Fluorouracil (5-FU) Toxicity:** Leucovorin significantly enhances the toxicity of 5-FU, particularly severe gastrointestinal adverse reactions (e.g., severe diarrhea, stomatitis, mucositis) and myelosuppression (leukopenia, thrombocytopenia). Deaths from severe toxicity have been reported when leucovorin is administered with 5-FU. It is imperative that leucovorin and 5-FU are administered under the supervision of a physician experienced in cancer chemotherapy. Close monitoring of patients for signs and symptoms of toxicity is essential, and dose modifications or discontinuation of 5-FU may be required. 2. **Masking of Vitamin B12 Deficiency:** Leucovorin should not be used as a primary treatment for pernicious anemia or other megaloblastic anemias due to vitamin B12 deficiency. Administration in such cases may mask the hematological symptoms of B12 deficiency while allowing neurological damage to progress, which can be irreversible. Thorough investigation to rule out vitamin B12 deficiency is mandatory before using leucovorin for megaloblastic anemia. 3. **Methotrexate Rescue Monitoring:** While leucovorin is critical for methotrexate rescue, the efficacy of rescue depends on correct dosing and timing. Failure to administer appropriate leucovorin doses at the correct time, guided by serum methotrexate levels and renal function, can lead to severe and potentially fatal methotrexate toxicity. 4. **Intrathecal Administration:** The intrathecal administration of leucovorin is not recommended and has been associated with severe neurotoxicity and seizures, and is not an approved route of administration.
- Leucovorin should never be used as a primary treatment for pernicious anemia or other megaloblastic anemias secondary to vitamin B12 deficiency.
- Administering leucovorin in such cases can mask the hematological manifestations of B12 deficiency while allowing the progression of severe and irreversible neurological damage.
- Before initiating leucovorin for megaloblastic anemia, an underlying vitamin B12 deficiency must be ruled out.
- When used to modulate 5-fluorouracil toxicity, leucovorin significantly potentiates the activity and toxicity of 5-FU, particularly severe gastrointestinal and hematological adverse events.
- Close monitoring for signs of mucositis, diarrhea, and myelosuppression is critical, and dosage adjustments or discontinuation of 5-FU may be necessary.
- Leucovorin should always be administered cautiously in patients with impaired renal function, as it may affect methotrexate clearance, and dose adjustments may be required in methotrexate rescue protocols.
- Intravenous administration should be performed slowly, as rapid infusion can lead to adverse reactions.
How it Works (Mechanism of Action)
Leucovorin, also known as folinic acid, is a 5-formyl derivative of tetrahydrofolic acid and is an active metabolite of folic acid. Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for conversion to tetrahydrofolate, the active coenzyme form necessary for various metabolic processes, including purine and pyrimidine synthesis, and consequently, DNA and RNA synthesis. Its mechanism of action varies depending on its clinical application.
1. **Methotrexate Rescue**: In this context, leucovorin acts as a biochemical rescue agent. Methotrexate inhibits DHFR, preventing the reduction of dihydrofolate to tetrahydrofolate, thereby depleting intracellular folate pools and inhibiting DNA synthesis in rapidly dividing cells. Leucovorin bypasses this enzymatic block by providing pre-formed tetrahydrofolate, allowing normal cells to resume essential metabolic functions and synthesize DNA, thereby protecting them from methotrexate's cytotoxic effects without significantly interfering with methotrexate's antineoplastic action in tumor cells.
2. **5-Fluorouracil (5-FU) Potentiation**: When used with 5-FU, leucovorin enhances the cytotoxic activity of 5-FU. 5-FU is a pyrimidine analog that is metabolized to 5-fluorodeoxyuridine monophosphate (5-FdUMP). 5-FdUMP inhibits thymidylate synthase, an enzyme critical for DNA synthesis. Leucovorin, as a folate coenzyme, stabilizes the binding of 5-FdUMP to thymidylate synthase, forming a ternary complex that potently and irreversibly inhibits the enzyme. This prolonged inhibition of thymidylate synthase leads to an increased anti-tumor effect of 5-FU by severely impairing DNA synthesis and repair in cancer cells.
3. **Folate Deficiency**: In cases of megaloblastic anemia due to folate deficiency, leucovorin directly supplies the necessary folate to support erythrocyte maturation and DNA synthesis, bypassing any metabolic defects that might prevent the utilization of dietary folic acid.
Commercial Brands (Alternatives)
No other brands found for this formula.